Kyverna Therapeutics, Inc. (KYTX) Earnings History
Annual and quarterly earnings data from 2021 to 2024
Loading earnings history...
KYTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
KYTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 100.0% | -418.3% | -411.3% |
| 2021 | 100.0% | -465.8% | -465.9% |
Download Data
Export KYTX earnings history in CSV or JSON format
Free sign-in required to download data
Kyverna Therapeutics, Inc. (KYTX) Earnings Overview
As of May 8, 2026, Kyverna Therapeutics, Inc. (KYTX) reported trailing twelve-month net income of -$161M. The company earned $-3.71 per diluted share over the past four quarters.
Looking at the long-term picture, KYTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$26M in fiscal 2021.
Kyverna Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CABA (-$168M net income), AUTL (-$225M net income, -2180.5% margin), IMVT (-$464M net income), KYTX has comparable earnings metrics. Compare KYTX vs CABA →
KYTX Earnings vs Peers
Earnings metrics vs comparable public companies
KYTX Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$127M | -111.2% | -$143M | $-3.33 | - | - |
| 2023 | -$60M | -108.9% | -$62M | $-0.00 | - | - |
| 2022 | -$29M | -9.7% | -$29M | $-1.12 | -411.3% | -418.3% |
| 2021 | -$26M | - | -$26M | $-1.02 | -465.9% | -465.8% |
See KYTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KYTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKYTX — Frequently Asked Questions
Quick answers to the most common questions about buying KYTX stock.
Is KYTX growing earnings?
KYTX TTM EPS: $-3.71. Net income: $-161M. Earnings growth: N/A.
What are KYTX's profit margins?
Kyverna Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are KYTX's earnings?
KYTX earnings data spans 2021-2024. The current earnings trend is N/A YoY. Historical data enables comparison across business cycles.